Cassava Sciences Stock Forecast, Price & News

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Cassava Sciences in the last twelve months. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Cassava Sciences stock.
View analyst ratings for Cassava Sciences or view top-rated stocks.

Wall Street analysts have given Cassava Sciences a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Cassava Sciences wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Cassava Sciences saw a increase in short interest in August. As of August 31st, there was short interest totaling 7,900,000 shares, an increase of 46.3% from the August 15th total of 5,400,000 shares. Based on an average daily trading volume, of 6,930,000 shares, the short-interest ratio is currently 1.1 days. Approximately 21.2% of the shares of the stock are sold short.
View Cassava Sciences' Short Interest.

Cassava Sciences is scheduled to release its next quarterly earnings announcement on Monday, November 8th 2021.
View our earnings forecast for Cassava Sciences.

Cassava Sciences, Inc. (NASDAQ:SAVA) posted its earnings results on Tuesday, August, 3rd. The company reported ($0.13) earnings per share for the quarter, hitting the Thomson Reuters' consensus estimate of ($0.13).
View Cassava Sciences' earnings history.

Cassava Sciences' stock was trading at $4.24 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, SAVA shares have increased by 1,133.7% and is now trading at $52.31.
View which stocks have been most impacted by COVID-19.

Cassava Sciences shares reverse split before market open on Wednesday, May 10th 2017. The 1-7 reverse split was announced on Monday, May 8th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, May 9th 2017. An investor that had 100 shares of Cassava Sciences stock prior to the reverse split would have 14 shares after the split.

4 brokers have issued 12-month price targets for Cassava Sciences' shares. Their forecasts range from $100.00 to $215.00. On average, they expect Cassava Sciences' share price to reach $146.00 in the next twelve months. This suggests a possible upside of 179.1% from the stock's current price.
View analysts' price targets for Cassava Sciences or view top-rated stocks among Wall Street analysts.

Some companies that are related to Cassava Sciences include Jazz Pharmaceuticals (JAZZ), BridgeBio Pharma (BBIO), Mawson Infrastructure Group (WIZP), Sarepta Therapeutics (SRPT), Legend Biotech (LEGN), Ultragenyx Pharmaceutical (RARE), Arrowhead Pharmaceuticals (ARWR), Blueprint Medicines (BPMC), HUTCHMED (HCM), I-Mab (IMAB), Allakos (ALLK), Perrigo (PRGO), Ionis Pharmaceuticals (IONS), Alkermes (ALKS) and Arvinas (ARVN).
View all of SAVA's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Cassava Sciences investors own include Inovio Pharmaceuticals (INO), NVIDIA (NVDA), Novavax (NVAX), Sorrento Therapeutics (SRNE), Advanced Micro Devices (AMD), NIO (NIO), DURECT (DRRX), Tesla (TSLA), OPKO Health (OPK) and Alibaba Group (BABA).

Cassava Sciences trades on the NASDAQ under the ticker symbol "SAVA."

Cassava Sciences' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (6.13%), Vanguard Group Inc. (4.56%), Jefferies Group LLC (0.00%), State Street Corp (2.17%), Geode Capital Management LLC (1.58%) and Susquehanna International Group LLP (0.00%). Company insiders that own Cassava Sciences stock include Eric Schoen, Remi Barbier and Sanford Robertson.
View institutional ownership trends for Cassava Sciences.

SAVA stock was sold by a variety of institutional investors in the last quarter, including Bleichroeder LP, Northern Trust Corp, Nuveen Asset Management LLC, Morgan Stanley, Morgan Stanley, Squarepoint Ops LLC, EAM Investors LLC, and Advisor Group Holdings Inc..
View insider buying and selling activity for Cassava Sciences or view top insider-selling stocks.

SAVA stock was bought by a variety of institutional investors in the last quarter, including Jefferies Group LLC, State Street Corp, Invesco Ltd., Simplex Trading LLC, Principal Financial Group Inc., Bank of America Corp DE, Rhenman & Partners Asset Management AB, and Citadel Advisors LLC. Company insiders that have bought Cassava Sciences stock in the last two years include Eric Schoen, Remi Barbier, and Sanford Robertson.
View insider buying and selling activity for Cassava Sciences or or view top insider-buying stocks.

Shares of SAVA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of SAVA stock can currently be purchased for approximately $52.31.

Cassava Sciences has a market capitalization of $2.09 billion. The company earns $-6,330,000.00 in net income (profit) each year or ($0.24) on an earnings per share basis.

Cassava Sciences employs 11 workers across the globe.

The official website for Cassava Sciences is www.cassavasciences.com.

Cassava Sciences is headquartered at 7801 N CAPITAL OF TEXAS HIGHWAY SUITE 260, AUSTIN TX, 78731.

Cassava Sciences' mailing address is 7801 N CAPITAL OF TEXAS HIGHWAY SUITE 260, AUSTIN TX, 78731. The company can be reached via phone at (512) 501-2444 or via email at [email protected].